Analyst Reco. AbbVie Inc.

Equities

ABBV

US00287Y1091

Market Closed - Nyse Other stock markets 04:05:15 2024-05-31 pm EDT			5-day change	1st Jan Change
161.2 ^USD	+3.15%		+2.66%	+4.05%

May. 31	Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday	MT
May. 31	AbbVie Receives European Medicine Agency Committee's Recommendation for Approval of Severe Bowel Disease Drug Candidate	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target	May. 17	MT
ANALYST RECOMMENDATIONS : Walmart, Netflix, Abbvie, Delta...	May. 17
Daiwa Securities Adjusts Price Target on AbbVie to $171 From $190	May. 08	MT
BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating	Apr. 29	MT
Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196	Apr. 29	MT
Barclays Adjusts Price Target on AbbVie to $187 From $195	Apr. 29	MT
Deutsche Bank Raises AbbVie's Price Target to $175 Form $170	Apr. 19	MT
Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating	Mar. 27	MT
Abbvie Insider Sold Shares Worth $3,716,757, According to a Recent SEC Filing	Mar. 22	MT
Abbvie Insider Sold Shares Worth $10,539,508, According to a Recent SEC Filing	Mar. 21	MT
ANALYST RECOMMENDATIONS : Abbvie, Align Technology; Ulta Beauty, United Airlines, Currys...	Mar. 15
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...	Feb. 26
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	Feb. 15	MT
UBS Adjusts Price Target on AbbVie to $172 from $165, Maintains Neutral Rating	Feb. 06	MT
Truist Adjusts Price Target on AbbVie to $195 From $180, Maintains Buy Rating	Feb. 06	MT
Piper Sandler Adjusts Price Target on AbbVie to $185 From $180, Maintains Overweight Rating	Feb. 05	MT
Morningstar Upgrades AbbVie to Hold From Sell, Increases Price Target to $168 From $137	Feb. 05	MT
Wells Fargo Adjusts Price Target on AbbVie to $200 From $180, Maintains Overweight Rating	Feb. 05	MT
Goldman Sachs Adjusts Price Target on AbbVie to $180 From $173, Keeps Buy Rating	Feb. 05	MT
BMO Capital Adjusts Price Target on AbbVie to $195 From $187, Maintains Outperform Rating	Feb. 05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. AbbVie Inc.

Equities

ABBV

US00287Y1091

Analyst Reco.

Filters